Magic bullet, part III?

Research output: Contribution to journalComment/debatepeer-review


In this issue of Blood, Oliveri and colleagues and Magro and colleagues report pilot trials using imatinib for steroid refractory sclerotic cGVHD, showing response rates of 79% and 50%.

Original languageEnglish (US)
Pages (from-to)498-499
Number of pages2
Issue number3
StatePublished - Nov 19 2009

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Magic bullet, part III?'. Together they form a unique fingerprint.

Cite this